

Financial news for IRWD dated on 2020-06-01: Credit Suisse Maintains Neutral on Ironwood Pharmaceuticals, Lowers Price Target to \$11

Financial news for IRWD dated on 2020-05-28: 70 Biggest Movers From Yesterday

Financial news for IRWD dated on 2020-05-27: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IRWD dated on 2020-05-27: Ironwood And AbbVie Report Phase II Trial Of MD-7246 Did Not Achieve Statistically Significant Improvements In Abdominal Pain Relative To Placebo, Companies Plan To Discontinue Development

Financial news for IRWD dated on 2020-05-18: Ironwood Pharmaceuticals Option Alert: Nov 20 \$15 Calls Sweep (21) near the Ask: 300 @ \$1.101 vs 0 OI; Ref=\$11.43

Financial news for IRWD dated on 2020-05-11: HC Wainwright & Co. Reiterates Neutral on Ironwood Pharmaceuticals, Lowers Price Target to \$11

Financial news for IRWD dated on 2020-05-07: Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to \$11

Financial news for IRWD dated on 2020-05-06: Ironwood Pharmaceuticals Q1 EPS \$0.040 Misses \$0.050 Estimate, Sales \$79.943M Beat \$78.660M Estimate

Financial news for IRWD dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for IRWD dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for IRWD dated on 2020-04-30: Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to \$15

Financial news for IRWD dated on 2020-04-28: Ironwood, Allergan Receive Notices Of Allowance For Patent Applications Covering 72 mcg Dose Of LINZESS

Financial news for IRWD dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to \$12

Financial news for IRWD dated on 2020-02-14: Ironwood Pharmaceuticals shares are trading lower after the company issued FY20 sales guidance below analyst estimates.

Financial news for IRWD dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for IRWD dated on 2020-02-13: Ironwood Pharmaceuticals Sees FY20 Sales \$360M-\$380M Vs. \$391.25M Est.

Financial news for IRWD dated on 2020-02-13: Ironwood Pharmaceuticals Q4 EPS \$0.3 Beats \$0.24 Estimate, Sales \$126.301M Beat \$111.85M Estimate

Financial news for IRWD dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for IRWD dated on 2020-01-22: Ironwood And Allergan Announce Settlement With Teva Resolving LINZESS Patent Litigation; Settlement Does Not Grant License To Teva With Regard To 72 mcg Patent Version Of LINZESS, Grants Teva License To Market 145 mcg And 290 mcg Generics Starting 2029

Financial news for IRWD dated on 2020-01-06: Ironwood Pharmaceuticals shares are trading higher after the company and Allergan announced they have reached an agreement with Sandoz resolving patent litigation brought in response to Sandoz's ANDA seeking approval to market generic versions of LINZESS.

Financial news for IRWD dated on 2020-01-06: Ironwood Pharma and Allergan Resolve Patent Litigation in Response to Sandoz's New Drug Application

Financial news for IRWD dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for IRWD dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for IRWD dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for IRWD dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for IRWD dated on 2019-12-19: Stocks That Hit 52-Week Highs On

Thursday

Financial news for IRWD dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for IRWD dated on 2019-12-18: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IRWD dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for IRWD dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for IRWD dated on 2019-11-20: Ironwood Pharmaceuticals Shares Up 2.78% For The Session; NOTE: Co. Previously Entered Gastrointestinal Disease Education And Promotional Agreement With Alnylam Pharmaceuticals For Givlaari, Which Today Received FDA Approval

Financial news for IRWD dated on 2019-10-31: Ironwood Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for IRWD dated on 2019-10-31: Ironwood Pharmaceuticals Earlier Reported Q3 Adj. EPS \$0.4 Beats \$0.1 Estimate, Sales \$131.167M Beat \$96.38M Estimate

Financial news for IRWD dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for IRWD dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for IRWD dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for IRWD dated on 2019-09-18: Ironwood Pharmaceuticals, AstraZeneca Amend LINZESS Collaboration in China

Financial news for IRWD dated on 2019-09-04: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

Financial news for IRWD dated on 2019-08-16: The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contempo Resubmission

Financial news for IRWD dated on 2019-08-13: Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter US GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Financial news for IRWD dated on 2019-08-01: Ironwood Pharmaceuticals Beginning On January 1, 2020, Co. Will No Longer Be Responsible For Supply Of Linacotide API To Astellas

Financial news for IRWD dated on 2019-07-31: Ironwood Pharmaceuticals' shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for IRWD dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for IRWD dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for IRWD dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for IRWD dated on 2019-07-10: Credit Suisse Assumes Ironwood Pharmaceuticals at Neutral

Financial news for IRWD dated on 2019-06-25: Shares of multiple drugmakers and biotech companies are trading higher after AbbVie announced it will acquire Allergan.

Financial news for IRWD dated on 2019-06-19: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IRWD dated on 2019-06-19: Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective

Financial news for IRWD dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for IRWD dated on 2019-06-18: Ironwood, Allergan Report Topline Data From Phase IIb Trial of LINZESS(r) (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation: Met All Primary, Secondary Endpoints

Financial news for IRWD dated on 2019-06-03: Ironwood Pharma, Allergan Report Initiation Of Patient Dosing In Phase II Trial Of MD-7246 In Patients With Abdominal Pain Associated With IBS-D

Financial news for IRWD dated on 2019-05-20: 60 Biggest Movers From Friday

Financial news for IRWD dated on 2019-05-17: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for IRWD dated on 2019-05-17: Ironwood Pharmaceuticals shares are trading higher after Sarissa Capital raised its stake in the company from 7.54 million shares to 9.49 million shares.

Financial news for IRWD dated on 2019-05-16: Ironwood Pharma 13D Filing From Sarissa Capital Shows Raised Stake From ~7.54M Shares To ~9.49M Shares, Or 6.1% Stake

Financial news for IRWD dated on 2019-05-03: 78 Biggest Movers From Yesterday

Financial news for IRWD dated on 2019-05-02: 54 Stocks Moving In Thursday's Mid-Day Session

Financial news for IRWD dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for IRWD dated on 2019-05-02: Ironwood Pharmaceuticals ; Sees FY2019 Sales \$370M-\$390M vs \$377.33M Est

Financial news for IRWD dated on 2019-05-02: Ironwood Pharmaceuticals Q1 EPS \$(0.26) Misses \$(0.18) Estimate, Sales \$68.73M Miss \$80.85M Estimate

Financial news for IRWD dated on 2019-04-02: Ironwood Pharmaceuticals shares are trading lower after the company said it expects 2019 sales to be below the analyst consensus estimate.

Financial news for IRWD dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for IRWD dated on 2019-04-01: Ironwood Pharma Sees FY19 Sales \$370M-\$390M vs \$387.1M Estimate

Financial news for IRWD dated on 2019-04-01: Ironwood Pharma Reports Completed Separation Of Cycleron Therapeutics

Financial news for IRWD dated on 2019-03-27: UPDATE: Morgan Stanley Upgrades Ironwood Pharmaceuticals As Firm Expects 'Linzess growth to stabilize in 2019, with prescription MiraLAX and potential additional label claims being the driver'

Financial news for IRWD dated on 2019-03-27: Benzinga's Top Upgrades, Downgrades For March 27, 2019

Financial news for IRWD dated on 2019-03-27: Morgan Stanley Upgrades Ironwood Pharmaceuticals to Equal-Weight, Raises Price Target to \$14

Financial news for IRWD dated on 2019-02-26: Ironwood Pharma Reports Cycleron Therapeutics Entered Deal For Private Placement Of Up To \$175M

Financial news for IRWD dated on 2019-02-25: Benzinga's Top Upgrades, Downgrades For February 25, 2019

Financial news for IRWD dated on 2019-02-25: H.C. Wainwright Upgrades Ironwood Pharmaceuticals to Neutral, Raises Price Target to \$14

Financial news for IRWD dated on 2019-02-14: 58 Biggest Movers From Yesterday

Financial news for IRWD dated on 2019-02-13: 42 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IRWD dated on 2019-02-13: Ironwood Pharmaceuticals shares are trading higher after the company reported Q4 EPS of \$(0.10), beating the \$(0.15) estimate and sales of \$130.69 million, beating the \$98.47 million estimate.

Financial news for IRWD dated on 2019-02-13: The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Financial news for IRWD dated on 2019-02-13: Ironwood Pharmaceuticals Q4 EPS \$(0.10) Beats \$(0.15) Estimate, Sales \$130.69M Beat \$98.47M Estimate

Financial news for IRWD dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for IRWD dated on 2019-01-24: 10 Biggest Price Target Changes For Thursday

Financial news for IRWD dated on 2019-01-24: Benzinga's Top Upgrades, Downgrades For January 24, 2019

Financial news for IRWD dated on 2019-01-24: Ironwood Pharma Announces Julie McHugh to Serve as Chair of the Board

Financial news for IRWD dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

Financial news for IRWD dated on 2019-01-24: JP Morgan Upgrades Ironwood Pharmaceuticals to Neutral, Raises Price Target to \$13

Financial news for IRWD dated on 2019-01-23: Ironwood Pharma Reports Initiation Of Phase 1 Trial Of IW-6463

Financial news for IRWD dated on 2019-01-15: Ironwood Pharmaceuticals Receives Approval Of LINZESS In China For Treatment Of Adults With IBS-C

Financial news for IRWD dated on 2019-01-04: Ironwood Pharmaceuticals Appoints Mark Mallon CEO

Financial news for IRWD dated on 2019-01-04: Ironwood Pharmaceuticals Picks AstraZeneca Executive To Be Next CEO

Financial news for IRWD dated on 2019-01-03: The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Financial news for IRWD dated on 2019-01-02: Ironwood And Allergan Announce Settlement With Mylan Resolving LINZESS Patent Litigation; Additional Details Not Disclosed

Financial news for IRWD dated on 2018-12-21: When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?

Financial news for IRWD dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for IRWD dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for IRWD dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for IRWD dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for IRWD dated on 2018-11-08: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018

Financial news for IRWD dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for IRWD dated on 2018-11-07: Benzinga's Top Upgrades, Downgrades For November 7, 2018

Financial news for IRWD dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for IRWD dated on 2018-11-07: JP Morgan Downgrades Ironwood Pharmaceuticals to Underweight

Financial news for IRWD dated on 2018-11-07: Credit Suisse Downgrades Ironwood Pharmaceuticals to Neutral

Financial news for IRWD dated on 2018-11-06: Ironwood Pharmaceuticals Q3 Adj. EPS \$(0.38) Misses \$(0.17) Estimate, Sales \$65.686M Miss \$93.63M Estimate

Financial news for IRWD dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for IRWD dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for IRWD dated on 2018-10-31: 64 Biggest Movers From Yesterday

Financial news for IRWD dated on 2018-10-30: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for IRWD dated on 2018-09-13: Ironwood Pharma Reports FDA Fast Track Designation For Praliciguat For Treatment Of Heart Failure with Preserved Ejection Fraction

Financial news for IRWD dated on 2018-08-06: Ironwood Pharmaceuticals shares down 7.5% after the company missed Q2 earnings estimates.

Financial news for IRWD dated on 2018-08-06: Earlier Ironwood Pharma Announced Termination of Its Licensing Agreement With AstraZeneca for U.S. Lesinurad Franchise

Financial news for IRWD dated on 2018-08-06: Ironwood Pharmaceuticals Q2 Adj. EPS \$(0.28) Misses \$(0.21) Estimate, Sales \$81.106M Miss \$82.6M Estimate

Financial news for IRWD dated on 2018-08-06: Ironwood Pharmaceuticals Q2 GAAP EPS \$(0.32) Misses \$(0.21) Estimate, Sales \$81.106M Miss \$82.6M Estimate

Financial news for IRWD dated on 2018-07-23: Benzinga's Top Upgrades, Downgrades For July 23, 2018

Financial news for IRWD dated on 2018-07-23: H.C. Wainwright Initiates Coverage On Ironwood Pharmaceuticals with Sell Rating, Announces \$12.50 Price Target

Financial news for IRWD dated on 2018-07-19: Delivering Alpha 2018: Everything You Need To Know

Financial news for IRWD dated on 2018-07-18: From Delivering Alpha Conference: Alex Denner Of Sarissa Capital Says Likes Ironwood Pharma, Medicines Co.

Financial news for IRWD dated on 2018-07-18: Benzinga's Top Upgrades, Downgrades For July 18, 2018

Financial news for IRWD dated on 2018-07-18: Cowen & Co. Downgrades Ironwood Pharmaceuticals to Market Perform

Financial news for IRWD dated on 2018-07-16: Ironwood Pharmaceuticals Starts Phase IIIb Study of Linaclotide

Financial news for IRWD dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for IRWD dated on 2018-06-23: Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at #ADA2018

Financial news for IRWD dated on 2018-06-21: Ironwood Pharma Initiates Pivotal Phase III Program for IW-3718

Financial news for IRWD dated on 2018-06-20: Ironwood Pharmaceuticals To Highlight Clinical And Preclinical Data For Praliciguat At American Diabetes Association's 78th Scientific Sessions

Financial news for IRWD dated on 2018-06-08: Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Amplphi Presents Positive Data, Agile To Cut Jobs

Financial news for IRWD dated on 2018-06-07: Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation For Olinciguat For Treatment Of Sick Cell Disease

Financial news for IRWD dated on 2018-06-06: Hearing Ironwood's olinciguat Granted FDA Orphan Drug Designation

Financial news for IRWD dated on 2018-06-06: Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

Financial news for IRWD dated on 2018-06-05: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements In Heartburn And Regurgitation Symptoms In Patients With Persistent GERD At Digestive Disease Week 2018

Financial news for IRWD dated on 2018-05-31: Ironwood Pharma Shareholder Sarissa Capital Issues Statement On Co., Says Plan To Separate Co.'s R&D Programs From Commercial Unit Is 'Good First Step Toward Creating Shareholder Value...'

Financial news for IRWD dated on 2018-05-14: Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees, Urges Shareholders to Vote "FOR" the Ironwood Director Nominees on the WHITE Proxy Card

Financial news for IRWD dated on 2018-05-09: Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate

Financial news for IRWD dated on 2018-05-09: Benzinga's Top Upgrades, Downgrades For May 9, 2018

Financial news for IRWD dated on 2018-05-09: Ironwood Pharmaceuticals Board Urges Shareholders to Vote "FOR" all Three of Ironwood's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Financial news for IRWD dated on 2018-05-09: Morgan Stanley Downgrades Ironwood Pharmaceuticals to Underweight

Financial news for IRWD dated on 2018-05-03: Ironwood and Allergan Announce Settlement With Aurobindo Pharma Over LINZESS Patent Litigation

Financial news for IRWD dated on 2018-05-02: Benzinga's Top Upgrades, Downgrades For May 2, 2018

Financial news for IRWD dated on 2018-05-02: UPDATE: Ironwood Urges Holders To Vote On WHITE Proxy Card For All Co. Director Nominees

Financial news for IRWD dated on 2018-05-02: Ironwood Files Proxy Materials, Sends Letter To Holders

Financial news for IRWD dated on 2018-05-02: Mizuho Upgrades Ironwood Pharmaceuticals to Buy

Financial news for IRWD dated on 2018-05-01: Ironwood Pharma Shares Down ~9% Following Earlier Resumption

Financial news for IRWD dated on 2018-05-01: Ironwood Sees Incurring Charges Related To Separation Deal; Will Offer Update On Impact Of Transaction Charges On FY18 During Q2 Investor Update

Financial news for IRWD dated on 2018-05-01: UPDATE: Ironwood Pharma Says Separation Of Units Expected To Result In 2 Independent Publicly Traded Cos.

Financial news for IRWD dated on 2018-05-01: Ironwood Reports Intent To Separate Soluble Guanylate Cyclase Business From Commercial, Gastrointestinal Business

Financial news for IRWD dated on 2018-05-01: Ironwood Pharma Shares To Resume Trade At 8:30 a.m. EDT

Financial news for IRWD dated on 2018-05-01: Ironwood Pharma Says Will Initiate Phase III Program For IW-3718 During Q3'18

Financial news for IRWD dated on 2018-05-01: Ironwood Pharma Q1 Adj. EPS \$(0.27) Misses \$(0.23) Est., Sales \$69.155M Misses \$78.9M Est.

Financial news for IRWD dated on 2018-05-01: Ironwood Pharma Shares Halted News Pending

Financial news for IRWD dated on 2018-04-09: Ironwood Pharma Shares Up 13.9%; Earlier Co Announced Receipt Of Notice From Sarissa Capital Mgmt That It Intends To Nominate Its CIO To The Co.'s Board

Financial news for IRWD dated on 2018-02-15: Ironwood Pharmaceuticals Reports Q4 Sales \$94.2M vs \$88M Est.

Financial news for IRWD dated on 2018-01-08: Ironwood Sees Sales From Linaclotide API Sales To Astellas Pharma \$20M+

Financial news for IRWD dated on 2018-01-08: Ironwood Pharma 8-K Shows Expectation For US Sales Of LINZESS ~\$700M In FY17

Financial news for IRWD dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for IRWD dated on 2018-01-05: Bank of America Downgrades Ironwood

## Pharmaceuticals From Buy to Underperform

Financial news for IRWD dated on 2017-12-21: Ironwood Pharma Reports Initiation Of Phase II Trial Of sGC Stimulator IW-1701 In Patients With Sick Cell Disease

Financial news for IRWD dated on 2017-12-06: The Market In 5 Minutes: Apple And China, Trump And Jerusalem, And Bitcoin

Financial news for IRWD dated on 2017-12-06: Mizuho Downgrades Ironwood Pharmaceuticals to Neutral

Financial news for IRWD dated on 2017-12-04: Ironwood Pharma Shares Tick To Session Lows, Down 2.4%, As Hearing Morgan Stanley Issued Cautious Comments On Co./Stock

Financial news for IRWD dated on 2017-12-04: UPDATE: Ironwood Pharma Says 'Data support advancement of IW-1973 for evaluation as a potential treatment for patients with diabetic nephropathy and for patients with heart failure with preserved ejection fraction'

Financial news for IRWD dated on 2017-12-04: Ironwood Pharma Reports Top-Line Phase IIa Data From IW-1973: 'Addition of IW-1973 to ongoing medical regimens used to treat diabetic patients with hypertension showed reductions in blood pressure, fasting plasma glucose, cholesterol and triglycerides...'

Financial news for IRWD dated on 2017-11-28: Ironwood Pharma Names William Huyett COO; Gina Consylman Promoted To CFO Role

Financial news for IRWD dated on 2017-11-27: Could The Street Be Underappreciating The Ironwood Pharma Pipeline?

Financial news for IRWD dated on 2017-11-27: Credit Suisse Initiates Coverage On Ironwood Pharmaceuticals with Outperform Rating, Announces \$19.00 Price Target

Financial news for IRWD dated on 2017-11-20: Seeing Notable Block Trade In Ironwood Pharmaceuticals Of 2.3M Shares At \$15.50/Share

Financial news for IRWD dated on 2017-11-08: Credit Suisse Healthcare Conference Concludes Today, Presenters Include: Community Health Systems, Innoviva, Ironwood Pharmaceuticals, Ignyta, Alnylam, and HCA Healthcare

Financial news for IRWD dated on 2017-11-02: Ironwood Pharma S-3 Shows Registration For Mixed Securities Shelf Offering

Financial news for IRWD dated on 2017-11-02: Ironwood Pharma Q3 Adj. EPS \$(0.18) vs \$(0.24) Est., Sales \$86.8M vs \$73.6M Est.

Financial news for IRWD dated on 2017-10-17: Seeing Notable Block Trade In Ironwood Pharmaceuticals Of 1.8M Shares At \$15.25/Share

Financial news for IRWD dated on 2017-09-13: Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna

Financial news for IRWD dated on 2017-09-07: Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals

Financial news for IRWD dated on 2017-08-21: Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout

Financial news for IRWD dated on 2017-08-04: Watch These 7 Huge Put Purchases In Friday Trade

Financial news for IRWD dated on 2017-08-03: Ironwood Reports Q2 Adj. EPS \$(0.28) vs \$(0.22) Est., Sales \$65.1M vs \$70.82M Est.

Financial news for IRWD dated on 2017-08-03: Benzinga's Option Alert Recap From August 3

Financial news for IRWD dated on 2017-08-03: Ironwood Pharm Option Alert: Sep 15 \$15 Puts at the Bid: 1000 @ \$0.6 vs 0 OI; Ref=\$16.635

Financial news for IRWD dated on 2017-07-21: Ironwood's Pipeline Needs Work, Analyst Downgrades

Financial news for IRWD dated on 2017-07-21: JP Morgan Downgrades Ironwood Pharmaceuticals to Neutral

Financial news for IRWD dated on 2017-07-20: UPDATE: Ironwood Says 'IW-3718 1500 mg also showed reductions in regurgitation frequency,' Will Advanced Into Phase III

Financial news for IRWD dated on 2017-07-20: UPDATE: Ironwood Says 'Greater than 50% of patients treated with IW-3718 1500 mg achieved a clinically meaningful reduction in heartburn severity'

Financial news for IRWD dated on 2017-07-20: Ironwood Pharma Reports Top-Line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease: Showed 'significant reduction in heartburn severity in patients with uncontrolled GERD'

Financial news for IRWD dated on 2017-06-15: Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes

Financial news for IRWD dated on 2017-06-08: Jefferies Health Care Conference Continues Today, Presenters Include: Ligand, Immunogen, TherapeuticsMD, Synergy Pharma, Ironwood, Acadia, Community Health Systems, & Celldex

Financial news for IRWD dated on 2017-05-17: Bank Of America Health Care Conference Continues Today; Presenters Include Celgene, Ionis, Neurocrine Biosciences, Cigna, GW Pharma, Allergan, Ironwood Pharma, Tenet Healthcare, Civitas Solutions, & Amgen

Financial news for IRWD dated on 2017-05-08: Ironwood Pharmaceuticals Says LINZESS U.S. Net Sales Grew To \$148M In Q1 2017, Remains On Track To Exceed \$1B In U.S. Annual Sales By 2020

Financial news for IRWD dated on 2017-05-03: Wells Fargo Initiates Coverage On Ironwood Pharmaceuticals with Outperform Rating

Financial news for IRWD dated on 2017-03-16: Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma

Financial news for IRWD dated on 2017-03-09: Ironwood Pharmaceuticals Holding R&D Day Today

Financial news for IRWD dated on 2017-02-21: Ironwood Pharmaceuticals Reports Q4 Adj. EPS \$(0.12) vs \$(0.24) Est., Sales \$87.459M vs \$77.34M Est.

Financial news for IRWD dated on 2017-01-29: Astellas, Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan

Financial news for IRWD dated on 2017-01-26: Allergan and Ironwood Pharmaceuticals Reports U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS

Financial news for IRWD dated on 2017-01-08: Ironwood Pharmaceuticals Sees Continued Strong LINZESS Growth and Margin Expansion in 2017 at #JPM17

Financial news for IRWD dated on 2017-01-04: Ironwood Announces New Drug Application for DUZALLO Has Been Accepted For FDA Review

Financial news for IRWD dated on 2016-12-22: Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 in IBS-C

Financial news for IRWD dated on 2016-12-19: Ironwood Pharma Gets Japanese Approval of LINZESS for IBS-C

Financial news for IRWD dated on 2016-11-13: UPDATE: Ironwood Reports Analysis Found that Patients Treated with Lesinurad Plus Allopurinol in CLEAR 1 and CLEAR 2 trials who Continued Treatment in the CLEAR Extension Study, Maintained Target sUA Levels over Full Two Years

Financial news for IRWD dated on 2016-11-13: Ironwood Highlights ZURAMPIC Phase III Extension Study Data at American College of Rheumatology 2016 Annual Meeting

Financial news for IRWD dated on 2016-11-03: Ironwood Pharma Reports Q3 Adj. EPS \$(0.18) vs \$(0.24) Est.; Reduces Expectation to Use Less Than \$50M in Cash for Operations During '16, Down from Forecast of Less Than \$70M Previously

Financial news for IRWD dated on 2016-10-03: Ironwood Pharma Reports US Availability of ZURAMPIC 200 mg Tablets for Patients with Uncontrolled Gout

Financial news for IRWD dated on 2016-09-23: 20 Stocks Which Rallied Three Days On Increasing Volume

Financial news for IRWD dated on 2016-09-22: BTIG Raises Ironwood Pharmaceuticals



## Price Target Ahead Of New Drug Launch

Financial news for IRWD dated on 2016-09-22: 10 Stocks With Three-Day Increasing Volume

Financial news for IRWD dated on 2016-08-04: Ironwood Pharmaceuticals Reports Q2 EPS \$(0.16) vs. Est. \$(0.15)

Financial news for IRWD dated on 2016-06-09: Ironwood Pharma, Allergan Report sNDA for 72 mcg Linacotide in Chronic Idiopathic Constipation Accepted for FDA Review

Financial news for IRWD dated on 2016-06-03: Ironwood Pharmaceuticals Closes Transaction with AstraZeneca for US Rights to Lesinurad

Financial news for IRWD dated on 2016-05-09: IronWood Q1 EPS (\$0.08) vs (\$0.14) est, Revenue \$66.0M vs \$53.6M est

Financial news for IRWD dated on 2016-05-04: Andrew Acker Speculating IRWD Could Be Bought By AGN

Financial news for IRWD dated on 2016-04-28: Option Alert: SWEEP (BUY) - IRWD June \$22.5 Put - 522 @ 11.462 in 76 orders. 522 traded. OI: 0

Financial news for IRWD dated on 2016-04-28: Adam Feuerstein Retweets Jacob Plieth: I've had it confirmed that \$IRWD report was removed from @PhaseVResearch site & Seekingalpha in response to complaint from FAERS data source

Financial news for IRWD dated on 2016-04-28: UPDATE: Appears Entire Phase Five Website is Down

Financial news for IRWD dated on 2016-04-28: Hearing Phase Five Research Removed Short Report on Ironwood from Website

Financial news for IRWD dated on 2016-04-28: Ironwood Shares Spiking To \$10.71/Share

Financial news for IRWD dated on 2016-04-26: Merrill Lynch Says Link Unlikely Between The 7 Reported AERS Deaths And Linzess

Financial news for IRWD dated on 2016-04-26: Mid-Afternoon Market Update: Crude Oil Up 3%; Amira Nature Foods Shares Tumble

Financial news for IRWD dated on 2016-04-26: Ironwood Pharma Sells Off to Low of \$9.69; May be Attributed to Short Piece from Phase Five Research

Financial news for IRWD dated on 2016-04-26: Option Alert: IRWD May16 5.0 Puts Sweep: 830 @ ASK \$0.10: 830 traded vs 1899 OI: Earnings 5/3 \$9.76 Ref

Financial news for IRWD dated on 2016-04-26: Traders Attributing Weakness in Ironwood to Negative Report from Phase Five Research

Financial news for IRWD dated on 2016-04-26: Astrazeneca Announces US Licensing Agreement With Ironwood; Includes US Rights to Zurampic; Lesinurad/Allopurinol Fixed-Dose Combination in Gout

Financial news for IRWD dated on 2016-04-06: Benzinga's Top Upgrades

Financial news for IRWD dated on 2016-04-06: Cowen & Company Upgrades Ironwood Pharmaceuticals to Outperform

Financial news for IRWD dated on 2016-04-05: Ironwood Pharmaceuticals Falls 6% Following Disappointing Phase 2a Study

Financial news for IRWD dated on 2016-04-05: Ironwood Pharmaceutical Shares Down \$0.70 At \$10.50 After IW-9179 Reports They Will Discontinue Development On Poor Top-Line Data

Financial news for IRWD dated on 2016-04-05: Ironwood Pharma Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in DG

Financial news for IRWD dated on 2016-03-23: Ironwood Pharmaceuticals Starts Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Financial news for IRWD dated on 2016-03-21: Benzinga's Top Initiations

Financial news for IRWD dated on 2016-03-21: Goldman Sachs Initiates Coverage on Ironwood Pharmaceuticals at Neutral, Announces \$14.00 PT, Likes LT Opportunity Coming From Pipeline Optionality

Financial news for IRWD dated on 2016-02-24: Ironwood Pharma Reports Filing by

Astellas of NDA in Japan with Linaclotide for Treatment of Adults with IBS-C

Financial news for IRWD dated on 2016-02-19: Shares Of Ironwood Spike Higher

Financial news for IRWD dated on 2016-02-19: Ironwood Pharma Spikes to High of \$9.05 on Volume

Financial news for IRWD dated on 2016-02-18: Ironwood Sees FY16 Opex \$255M-\$285M

Financial news for IRWD dated on 2016-02-18: Ironwood Pharma Reports Prelim. Q4 Adj. EPS ~\$(0.10) vs \$(0.17) Est.

Financial news for IRWD dated on 2016-02-18: UPDATE: Ironwood Says Expects to Initiate Multiple Phase II Studies in 2016

Financial news for IRWD dated on 2016-02-18: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701

Financial news for IRWD dated on 2016-01-12: Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside

Financial news for IRWD dated on 2016-01-11: Ironwood Pharmaceuticals Expects \$1B In LINZESS Annual net Sales By 202, More Than \$2B linaclotide US Peak Sale Potential

Financial news for IRWD dated on 2016-01-08: Benzinga's Top Initiations

Financial news for IRWD dated on 2016-01-08: Mizuho Securities Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces \$15.00 PT

Financial news for IRWD dated on 2015-12-28: Wedbush Offers Weekly Retail Sales Tracker for Recently-Launched Drugs: Ironwood's LINZESS Total Srips Up 0.4% WoW, New Srips Down 0.8% WoW, Repeat Srips Up 1.4% WoW

Financial news for IRWD dated on 2015-12-11: BTIG Earlier Initiated Ironwood Pharma with Buy Rating, \$15 Target, Cited 'improving visibility with its GI-focused pipeline'

Financial news for IRWD dated on 2015-11-30: BZ NOTE: While Astellas, Ironwood Top-Line Data Was Positive; Diarrhea Rates In Trial For Linaclotide Registered 9.6% vs. 0.4% For Placebo

Financial news for IRWD dated on 2015-11-30: Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan, Has Met All Primary Endpoints In All 8 Phase III/IIb Clinical Trials

Financial news for IRWD dated on 2015-11-30: UPDATE: Ironwood, Allergan to Make Decision Related to Advancement of OIC Program Following Review of Results from Linaclotide Colonic Release Phase IIB Trial

Financial news for IRWD dated on 2015-11-30: UPDATE: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Financial news for IRWD dated on 2015-11-30: Ironwood Offers Top-Line Data from Phase 3 Trial of Linaclotide: Says Met Primary Endpoint

Financial news for IRWD dated on 2015-11-03: Ironwood Reported Q3 GAAP Loss of \$0.33/Share, Adj. Loss of \$0.25/Share vs Loss of \$0.20/Share Est.

Financial news for IRWD dated on 2015-11-02: Ironwood, Allergan Announce Initiation of Phase IIb Trial of Linaclotide Colonic Release

Financial news for IRWD dated on 2015-10-27: US Stock Futures Edge Lower Ahead Of Earnings

Financial news for IRWD dated on 2015-10-27: Allergan Acquires Rights to Ironwood's CONSTELLA from Almirall 40+ Countries

Financial news for IRWD dated on 2015-10-13: Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation

Financial news for IRWD dated on 2015-08-05: Ironwood Pharma Reports Q2 Loss of \$0.34/Share vs Loss of \$0.22/Share Est., Sales \$27.7M vs \$36.5M Est.

Financial news for IRWD dated on 2015-08-05: Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.

Financial news for IRWD dated on 2015-07-22: Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973

Financial news for IRWD dated on 2015-07-09: New Studies And Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials

Financial news for IRWD dated on 2015-07-08: Benzinga's Top #PreMarket Gainers

Financial news for IRWD dated on 2015-07-08: AstraZeneca, Ironwood Announce Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linacotide Approval in China

Financial news for IRWD dated on 2015-06-17: JP Morgan Defends Ironwood Pharma

Financial news for IRWD dated on 2015-06-17: Wedbush Cuts Target on Ironwood Pharma from \$13 to \$11, Highlights Positive Ph3 for Potential Linzess Competitor Plecanatide

Financial news for IRWD dated on 2015-06-10: Ironwood Pharmaceuticals Prices \$300M of Convertible Senior Notes

Financial news for IRWD dated on 2015-04-27: Benzinga's Top Initiations

Financial news for IRWD dated on 2015-04-27: Bank of America Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces \$19.00 PT

Financial news for IRWD dated on 2015-03-19: Ironwood Pharma Shares Move Higher After-Hours on Daily Mail Report it Could be Takeover Target

Financial news for IRWD dated on 2015-03-13: Friday's After-Hours Movers: Akorn, Rosetta Resources And More

Financial news for IRWD dated on 2015-03-09: Exact Sciences & Ironwood Enter Co-Promotion For Cologuard

Financial news for IRWD dated on 2015-03-05: Ironwood Pharma Initiates Phase 1 Clinical Study of sGC Stimulator IW-1973

Financial news for IRWD dated on 2015-03-05: Ironwood Pharmaceuticals Initiates Phase I Clinical Study of Sgc Stimulator IW-1973

Financial news for IRWD dated on 2015-03-04: Barclays Expands Coverage To 7 New Biotech Stocks

Financial news for IRWD dated on 2015-03-04: Barclays Initiates Coverage on Ironwood Pharmaceuticals at Equal-weight, Announces \$18.00 PT

Financial news for IRWD dated on 2015-02-12: Ironwood Pharma Reports Q4 EPS Loss \$0.27 Vs Est \$0.21, Sales \$38.1M

Financial news for IRWD dated on 2015-02-06: Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals to Hold

Financial news for IRWD dated on 2015-02-04: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Financial news for IRWD dated on 2015-01-13: The World's Top 10 Financial Bloggers

Financial news for IRWD dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for IRWD dated on 2014-12-09: Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179

Financial news for IRWD dated on 2014-11-20: Ironwood Earns \$15M Payment From Astellas

Financial news for IRWD dated on 2014-11-04: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linacotide

Financial news for IRWD dated on 2014-11-04: Ironwood Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.30) vs \$(0.32) Est

Financial news for IRWD dated on 2014-10-20: Ironwood Presents IW-9179 Phase IIa Data At American College Of Gastroenterology 2014 Annual Scientific Meeting

Financial news for IRWD dated on 2014-10-16: Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linacotide In Adult Patients With Opioid-Induced

Constipation

Financial news for IRWD dated on 2014-09-04: Markets Open Higher; VeriFone Profit Tops Street View

Financial news for IRWD dated on 2014-09-04: Benzinga's Top Downgrades

Financial news for IRWD dated on 2014-09-04: Cowen & Company Downgrades Ironwood Pharmaceuticals To Market Perform

Financial news for IRWD dated on 2014-09-04: Cowen & Company Downgrades Ironwood Pharmaceuticals, Inc. to Market Perform, Lowers PT to \$10.50

Financial news for IRWD dated on 2014-09-02: Ironwood Names Thomas Graney as CFO

Financial news for IRWD dated on 2014-08-04: Ironwood Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.44) vs \$(0.36) Est; Revenue of \$6.84M vs \$15.57M Est

Financial news for IRWD dated on 2014-07-09: Furey Research Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Buy, Announces \$20.00 PT

Financial news for IRWD dated on 2014-06-18: Wallachbeth Capital Initiated Coverage on Ironwood Pharma with a Hold Rating and \$16 Price Target

Financial news for IRWD dated on 2014-06-10: Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Financial news for IRWD dated on 2014-06-03: Ironwood Pharmaceuticals Chairman Roberts Sells 411,154 Shares @\$14.52/Share -Form 4

Financial news for IRWD dated on 2014-05-16: Option Alert: Ironwood Pharma Jun \$12.5 Put; 1,600 Contracts Traded vs 1,059 OI; Currently \$13.64

Financial news for IRWD dated on 2014-02-12: Ironwood Pharmaceuticals Prices 13.725M Share Offering at \$12.75/Share

Financial news for IRWD dated on 2014-02-10: Ironwood Pharmaceuticals Announces \$150M Proposed Public Offering of Common Stock

Financial news for IRWD dated on 2014-01-21: Mid-Day Market Update: Dow Tumbles Over 100 Points; Signature Bank Shares Gain On Strong Earnings

Financial news for IRWD dated on 2014-01-21: Mid-Morning Market Update: Markets Mixed; Verizon Posts Q4 Profit

Financial news for IRWD dated on 2014-01-21: Ironwood Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.43) vs \$(0.50) Est; Revenue of \$5.03M vs \$7.13M Est

Financial news for IRWD dated on 2014-01-08: Ironwood Pharma Will Cut ~10% of Jobs, Sees \$4-4.5M Charge

Financial news for IRWD dated on 2013-12-18: Option Alert: Ironwood Pharmaceuticals May \$20 Call; 2,669 Contract Trade at Ask @\$0.30; Currently \$10.50

Financial news for IRWD dated on 2013-12-12: Ironwood Pharma Says Exploring Ways to Strengthen Linzess Clinical Profile

Financial news for IRWD dated on 2013-10-24: UPDATE: Cowen & Company Upgraded Ironwood Pharmaceuticals

Financial news for IRWD dated on 2013-10-24: Cowen & Company Upgrades Ironwood Pharmaceuticals, Inc. to Outperform, Maintains \$14.00 PT

Financial news for IRWD dated on 2013-10-22: Stocks Hitting 52-Week Lows

Financial news for IRWD dated on 2013-10-22: Ironwood Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.51) vs \$(0.57) Est; Revenue of \$4.93M vs \$6.54M Est; Reaffirms Outlook

Financial news for IRWD dated on 2013-09-23: Ironwood Pharma Shares Lower Following Market Perform Rating, \$15 Target at BMO

Financial news for IRWD dated on 2013-09-17: Goldman Sachs Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Sell, Announces \$9.50 PT

Financial news for IRWD dated on 2013-07-24: UPDATE: Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals Following Model Update

Financial news for IRWD dated on 2013-07-24: Jefferies Maintains Hold on Ironwood Pharmaceuticals, Inc., Lowers PT to \$12.00

Financial news for IRWD dated on 2013-07-24: Janney Capital Upgrades Ironwood Pharmaceuticals, Inc. to Buy

Financial news for IRWD dated on 2013-07-24: Benzinga's Top Upgrades

Financial news for IRWD dated on 2013-07-24: Cantor Fitzgerald Upgrades Ironwood Pharmaceuticals, Inc. to Hold, Raises PT to \$10.00

Financial news for IRWD dated on 2013-07-23: Benzinga's Top Pre-Market Gainers

Financial news for IRWD dated on 2013-07-23: Ironwood Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.57) vs \$(0.68) Est; Revenue of \$9.66M vs \$6.48M Est

Financial news for IRWD dated on 2013-06-28: Stocks Hitting 52-Week Lows

Financial news for IRWD dated on 2013-06-25: UPDATE: Cantor Fitzgerald Lowers PT on Ironwood Pharmaceuticals on Lower than Expected Constella Pricing

Financial news for IRWD dated on 2013-06-21: Benzinga's Top Initiations

Financial news for IRWD dated on 2013-06-21: Credit Suisse Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Outperform, Announces \$16.00 PT

Financial news for IRWD dated on 2013-06-12: Ironwood Pharma Reports Potential Reduction in Commercial Launch Milestones from \$20M to \$17M

Financial news for IRWD dated on 2013-06-04: Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters' Option in Public Offering of Common Stock

Financial news for IRWD dated on 2013-05-30: UPDATE: Webush Upgrades Ironwood Pharmaceuticals on Completed Financing

Financial news for IRWD dated on 2013-05-30: Benzinga's Top Upgrades

Financial news for IRWD dated on 2013-05-30: Wedbush Upgrades Ironwood Pharmaceuticals, Inc. to Neutral, Maintains \$12.00 PT

Financial news for IRWD dated on 2013-05-21: Benzinga's Top Pre-Market Losers

Financial news for IRWD dated on 2013-05-20: Ironwood Pharmaceuticals Announces 10.5M Share Proposed Public Offering of Common Stock

Financial news for IRWD dated on 2013-05-06: Mid-Morning Market Update: Markets Open Mixed, Tyson Posts Downbeat Profit

Financial news for IRWD dated on 2013-05-06: Cowen & Company Downgrades Ironwood Pharmaceuticals, Inc. to Neutral

Financial news for IRWD dated on 2013-04-24: UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals to Underperform on Higher Lincess Costs

Financial news for IRWD dated on 2013-04-24: UPDATE: Morgan Stanley Downgrades Ironwood Pharmaceuticals to Equal-Weight on Lower Lincess Sales Estimates

Financial news for IRWD dated on 2013-04-24: Wedbush Downgrades Ironwood Pharmaceuticals, Inc. to Underperform, Lowers PT to \$12.00

Financial news for IRWD dated on 2013-04-24: Morgan Stanley Downgrades Ironwood Pharmaceuticals, Inc. to Equal-weight, Lowers PT to \$18.00

Financial news for IRWD dated on 2013-04-23: Market Wrap for Tuesday, April 23: Major Averages Climb Better Than 1% Despite Mini Flash-Crash

Financial news for IRWD dated on 2013-04-23: Aegis Capital Maintains Buy on Ironwood Pharmaceuticals, Inc., Lowers PT to \$17.00

Financial news for IRWD dated on 2013-04-23: Mid-Morning Market Update: Markets Surge On Earnings, Lockheed Martin Posts Upbeat Profit

Financial news for IRWD dated on 2013-04-23: Ironwood Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.87) vs \$(0.64) Est; Revenue of \$3.30M vs \$8.94M Est

Financial news for IRWD dated on 2013-03-15: UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Lincess Survey

Financial news for IRWD dated on 2013-03-15: Credit Suisse Upgrades Ironwood Pharmaceuticals, Inc. to Outperform, Raises PT to \$24.00

Financial news for IRWD dated on 2013-03-12: Bank of America Raises PT on Ironwood Pharmaceuticals on Positive Prescription Data

Financial news for IRWD dated on 2013-03-12: Bank of America Maintains Neutral on Ironwood Pharmaceuticals, Inc., Raises PO to \$18.00

Financial news for IRWD dated on 2013-02-13: UPDATE: Wedbush Upgrades Ironwood Pharmaceuticals to Neutral on LINZESS Strength

Financial news for IRWD dated on 2013-02-13: Wedbush Upgrades Ironwood Pharmaceuticals, Inc. to Neutral, Raises PT to \$13.00

Financial news for IRWD dated on 2013-02-11: Ironwood Pharma Promotes Dr. Mark Currie to Senior VP, Chief Scientific Officer, Pres of R&D

Financial news for IRWD dated on 2013-01-31: Janney Capital Initiates Coverage on Ironwood Pharmaceuticals, Inc. at Neutral, Announces \$14.00 PT

Financial news for IRWD dated on 2013-01-16: Ironwood Pharma Shares Tumble Follow UBS Downgrade to Sell

Financial news for IRWD dated on 2013-01-15: JP Morgan Maintains Overweight on Ironwood Pharmaceuticals, Inc., Raises PT to \$25.00

Financial news for IRWD dated on 2013-01-15: Aegis Capital Maintains Buy on Ironwood Pharmaceuticals, Inc., Raises PT to \$19.00

Financial news for IRWD dated on 2013-01-15: Ironwood Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.41) vs \$(0.49) Est; Revenue of \$27.0M vs \$16.85M Est

Financial news for IRWD dated on 2013-01-15: Earnings Scheduled For January 15, 2013

Financial news for IRWD dated on 2012-12-21: Ironwood Starts Phase I Trial of Anti-Anxiety Drug in US

Financial news for IRWD dated on 2012-12-17: Ironwood Pharma, Forest Labs' Announces US Availability of Linzess to Treat IBS with Constipation

Financial news for IRWD dated on 2012-11-28: EC Approves Ironwood's Constella for Treatment of Irritable Bowel Syndrome with Constipation in Adults

Financial news for IRWD dated on 2012-11-08: Mizuho Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces PT of \$22

Financial news for IRWD dated on 2012-10-24: Aegis Capital Maintains Ironwood Pharmaceuticals at Buy, Raises PT from \$17 to \$18

Financial news for IRWD dated on 2012-10-23: Ironwood and AstraZeneca Announce Linaclotide Collaboration for China

Financial news for IRWD dated on 2012-10-16: From Earlier: Ironwood Pharmaceuticals Reports Q3 EPS \$0.42 May Not Compare to \$0.13 Est; Revenues \$96.4M vs \$75.90M Est

Financial news for IRWD dated on 2012-08-30: UPDATE: Ironwood Pharmaceuticals Rises, then Falls Following FDA Approval

Financial news for IRWD dated on 2012-08-30: Ironwood Pharmaceuticals Resumes Trading

Financial news for IRWD dated on 2012-08-30: PREVIEW: Ironwood Pharmaceuticals to Resume Trading at 2:20pm

Financial news for IRWD dated on 2012-08-30: Ironwood and Forest Announce FDA Approval of LINZESSTM

Financial news for IRWD dated on 2012-08-30: UPDATE: Ironwood Pharmaceuticals Still Halted; No Resumption Time

Financial news for IRWD dated on 2012-08-30: Ironwood, Forest Labs Get FDA Approval for Linzess

Financial news for IRWD dated on 2012-08-30: Ironwood Pharma Trade Halt

Financial news for IRWD dated on 2012-08-20: UPDATE: Cantor Fitzgerald Raises PT to \$8 on Ironwood Pharmaceuticals; Maintains Sell

Financial news for IRWD dated on 2012-08-20: Cantor Fitzgerald Maintains Ironwood Pharmaceuticals at Sell, Raises PT from \$7 to \$8

Financial news for IRWD dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for IRWD dated on 2012-07-18: UPDATE: Cantor Fitzgerald Reiterates Sell Rating, Lowers PT on Ironwood Pharmaceuticals

Financial news for IRWD dated on 2012-07-18: Cantor Fitzgerald Maintains Ironwood Pharmaceuticals at Sell, Lowers PT from \$10 to \$7

Financial news for IRWD dated on 2012-07-09: UPDATE: Aegis Capital Initiated Ironwood Pharmaceuticals with Buy, \$17 PT; Unique Gastrointestinal Opportunity

Financial news for IRWD dated on 2012-07-09: Aegis Capital Initiates Coverage on Ironwood Pharmaceuticals at Buy, Announces PT of \$17

Financial news for IRWD dated on 2012-05-08: Bank of America Maintains Ironwood Pharmaceuticals at Neutral, Lowers PO from \$16 to \$15

Financial news for IRWD dated on 2012-05-01: Ladenburg Thalmann Maintains Ironwood Pharmaceuticals at Buy, Lowers PT from \$17 to \$16

Financial news for IRWD dated on 2012-05-01: Ironwood Pharmaceuticals Provides First Quarter 2012 Investor Update

Financial news for IRWD dated on 2012-04-23: From Earlier: Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012

Financial news for IRWD dated on 2012-04-12: UBS Initiates Coverage on Ironwood Pharmaceuticals at Neutral, Announces PT of \$14

Financial news for IRWD dated on 2012-03-05: UPDATE: Wedbush Downgrades Ironwood Pharmaceuticals; Lowers PT

Financial news for IRWD dated on 2012-03-05: Bank of America: Zelnorm vs. linaclotide

Financial news for IRWD dated on 2012-03-05: Wedbush Securities Downgrades Ironwood Pharmaceuticals from Outperform to Underperform, Lowers PT from \$20 to \$8

Financial news for IRWD dated on 2012-02-29: UPDATE: Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals, Lowers PT

Financial news for IRWD dated on 2012-02-29: Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals from Hold to Sell, Maintains PT at \$10

Financial news for IRWD dated on 2012-02-13: Ironwood Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock

Financial news for IRWD dated on 2012-02-10: From Earlier: Ironwood Pharmaceuticals Prices Public Offering of 5.25M Shares at \$15.09

Financial news for IRWD dated on 2012-02-09: From Earlier: Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide

Financial news for IRWD dated on 2012-02-08: Ironwood Pharmaceuticals Announces Proposed Public Offering of 5.25M Shares

Financial news for IRWD dated on 2012-02-08: Ironwood Pharmaceuticals Spiking Lower

Financial news for IRWD dated on 2012-01-04: Ironwood Pharmaceuticals and Bionomics Announce Collaboration, Research, and License Agreement

Financial news for IRWD dated on 2012-01-04: European Patent Office Upholds Synergy Pharmaceuticals' Grant of Claims to Plecanatide

Financial news for IRWD dated on 2011-12-13: Synergy Pharmaceuticals Files Suit Against Ironwood Pharmaceuticals

Financial news for IRWD dated on 2011-12-13: Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals and its Chief Scientific Officer

Financial news for IRWD dated on 2011-11-07: Ironwood Pharmaceuticals Reports Q3 Revenues \$12.20M vs \$12.92M Est

Financial news for IRWD dated on 2011-10-24: Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review

Financial news for IRWD dated on 2011-09-29: Ironwood Announces Linaclotide European Regulatory Submission for the Treatment of Irritable Bowel Syndrome with Constipation

Financial news for IRWD dated on 2011-09-01: Notable Call Options Activity in Ironwood Pharmaceuticals

Financial news for IRWD dated on 2011-08-12: Ladenburg Thalmann Lowers PT on Ironwood Pharmaceuticals To \$16

Financial news for IRWD dated on 2011-08-11: Earnings Scheduled For August 11

Financial news for IRWD dated on 2011-08-09: Ironwood Pharmaceuticals and Forest Laboratories Announce Submission of New Drug Application for Linaclootide

Financial news for IRWD dated on 2011-08-09: Will FDA Push Through New Constipation Drug?

Financial news for IRWD dated on 2011-08-09: Ironwood Pharmaceuticals Halted, Pending News

Financial news for IRWD dated on 2011-05-12: Earnings Scheduled For May 12 (DRYS, JWN, AHII, KSS, DAR, NVDA, CACH, XIN, ACAT, BBOX, ESLR, CXPO, IRWD, CTFO, TREE, CYCC, CXDC)

Financial news for IRWD dated on 2011-05-11: UPDATE: Bank of America Merrill Lynch Raises PO on Ironwood Pharmaceuticals to \$16 (IRWD)

Financial news for IRWD dated on 2011-05-04: Ironwood and Forest to Present Linaclootide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation (IRWD, FRX)

Financial news for IRWD dated on 2011-04-15: J.P. Morgan Raises PT On IRWD To \$21

Financial news for IRWD dated on 2011-04-14: Ironwood Pharmaceuticals Hits 52-Week High (IRWD)

Financial news for IRWD dated on 2011-04-14: Ironwood Pharmaceuticals Hits 52-Week High (IRWD)

Financial news for IRWD dated on 2011-03-18: Morgan Stanley Initiates OW Rating For IRWD

Financial news for IRWD dated on 2011-03-03: Ironwood Pharmaceuticals Reports Q4 Loss of \$0.12 per share

Financial news for IRWD dated on 2011-03-03: Earnings Scheduled For March 3 (MRVL, HNZ, KR, NOVL, ALTH, BIG, BRLI, ACU, CLDX, ADUS, ACCL, IRWD)

Financial news for IRWD dated on 2011-01-18: Ironwood and Protagonist Establish Collaboration

Financial news for IRWD dated on 2011-01-18: Forest Labs Impresses Again - Analyst Blog

Financial news for IRWD dated on 2011-01-18: Forest Labs Impresses Again - Analyst Blog

Financial news for IRWD dated on 2010-11-02: J.P. Morgan Reiterates Overweight Rating On Shares Of Ironwood Pharmaceuticals

Financial news for IRWD dated on 2010-09-14: Benzinga's Top Pre-Market NASDAQ Gainers (IRWD, AINV, CRUS, AONE)

Financial news for IRWD dated on 2010-02-01: Ironwood (IRWD) To Raise \$267 Million Through IPO